Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD : A Cohort Sub-Study in a Randomized Trial Population. / Kamstrup, Peter; Sand, Jannie Marie Bulow; Ulrik, Charlotte Suppli; Janner, Julie; Ronn, Christian Philip; Ronnow, Sarah Rank; Leeming, Diana Julie; Jensen, Sidse Graff; Wilcke, Torgny; Mathioudakis, Alexander G.; Miravitlles, Marc; Lapperre, Therese; Bendstrup, Elisabeth; Frikke-Schmidt, Ruth; Murray, Daniel D.; Itenov, Theis; Bossios, Apostolos; Nielsen, Susanne Dam; Vestbo, Jorgen; Biering-Sorensen, Tor; Karsdal, Morten; Jensen, Jens-Ulrik; Sivapalan, Pradeesh.

In: Biomedicines, Vol. 10, No. 8, 2011, 2022.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Kamstrup, P, Sand, JMB, Ulrik, CS, Janner, J, Ronn, CP, Ronnow, SR, Leeming, DJ, Jensen, SG, Wilcke, T, Mathioudakis, AG, Miravitlles, M, Lapperre, T, Bendstrup, E, Frikke-Schmidt, R, Murray, DD, Itenov, T, Bossios, A, Nielsen, SD, Vestbo, J, Biering-Sorensen, T, Karsdal, M, Jensen, J-U & Sivapalan, P 2022, 'Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population', Biomedicines, vol. 10, no. 8, 2011. https://doi.org/10.3390/biomedicines10082011

APA

Kamstrup, P., Sand, J. M. B., Ulrik, C. S., Janner, J., Ronn, C. P., Ronnow, S. R., Leeming, D. J., Jensen, S. G., Wilcke, T., Mathioudakis, A. G., Miravitlles, M., Lapperre, T., Bendstrup, E., Frikke-Schmidt, R., Murray, D. D., Itenov, T., Bossios, A., Nielsen, S. D., Vestbo, J., ... Sivapalan, P. (2022). Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population. Biomedicines, 10(8), [2011]. https://doi.org/10.3390/biomedicines10082011

Vancouver

Kamstrup P, Sand JMB, Ulrik CS, Janner J, Ronn CP, Ronnow SR et al. Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population. Biomedicines. 2022;10(8). 2011. https://doi.org/10.3390/biomedicines10082011

Author

Kamstrup, Peter ; Sand, Jannie Marie Bulow ; Ulrik, Charlotte Suppli ; Janner, Julie ; Ronn, Christian Philip ; Ronnow, Sarah Rank ; Leeming, Diana Julie ; Jensen, Sidse Graff ; Wilcke, Torgny ; Mathioudakis, Alexander G. ; Miravitlles, Marc ; Lapperre, Therese ; Bendstrup, Elisabeth ; Frikke-Schmidt, Ruth ; Murray, Daniel D. ; Itenov, Theis ; Bossios, Apostolos ; Nielsen, Susanne Dam ; Vestbo, Jorgen ; Biering-Sorensen, Tor ; Karsdal, Morten ; Jensen, Jens-Ulrik ; Sivapalan, Pradeesh. / Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD : A Cohort Sub-Study in a Randomized Trial Population. In: Biomedicines. 2022 ; Vol. 10, No. 8.

Bibtex

@article{fbc4a8cca79d4b62a0d6814ef2060a8f,
title = "Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population",
abstract = "Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65-1.48), VWF-N: HR 1.56 (95% CI 1.07-2.27), and VWF-A: HR 0.78 (95% CI 0.52-1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population.",
keywords = "COPD exacerbation, major cardiovascular events, coagulation, biomarkers, von Willebrand factor, cross-linked fibrin degradation, VON-WILLEBRAND-FACTOR, D-DIMER, ADAMTS13 ACTIVITY, FACTOR ANTIGEN, MORTALITY",
author = "Peter Kamstrup and Sand, {Jannie Marie Bulow} and Ulrik, {Charlotte Suppli} and Julie Janner and Ronn, {Christian Philip} and Ronnow, {Sarah Rank} and Leeming, {Diana Julie} and Jensen, {Sidse Graff} and Torgny Wilcke and Mathioudakis, {Alexander G.} and Marc Miravitlles and Therese Lapperre and Elisabeth Bendstrup and Ruth Frikke-Schmidt and Murray, {Daniel D.} and Theis Itenov and Apostolos Bossios and Nielsen, {Susanne Dam} and Jorgen Vestbo and Tor Biering-Sorensen and Morten Karsdal and Jens-Ulrik Jensen and Pradeesh Sivapalan",
year = "2022",
doi = "10.3390/biomedicines10082011",
language = "English",
volume = "10",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "M D P I AG",
number = "8",

}

RIS

TY - JOUR

T1 - Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD

T2 - A Cohort Sub-Study in a Randomized Trial Population

AU - Kamstrup, Peter

AU - Sand, Jannie Marie Bulow

AU - Ulrik, Charlotte Suppli

AU - Janner, Julie

AU - Ronn, Christian Philip

AU - Ronnow, Sarah Rank

AU - Leeming, Diana Julie

AU - Jensen, Sidse Graff

AU - Wilcke, Torgny

AU - Mathioudakis, Alexander G.

AU - Miravitlles, Marc

AU - Lapperre, Therese

AU - Bendstrup, Elisabeth

AU - Frikke-Schmidt, Ruth

AU - Murray, Daniel D.

AU - Itenov, Theis

AU - Bossios, Apostolos

AU - Nielsen, Susanne Dam

AU - Vestbo, Jorgen

AU - Biering-Sorensen, Tor

AU - Karsdal, Morten

AU - Jensen, Jens-Ulrik

AU - Sivapalan, Pradeesh

PY - 2022

Y1 - 2022

N2 - Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65-1.48), VWF-N: HR 1.56 (95% CI 1.07-2.27), and VWF-A: HR 0.78 (95% CI 0.52-1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population.

AB - Cardiovascular diseases are common in patients with chronic obstructive pulmonary disease (COPD). Clot formation and resolution secondary to systemic inflammation may be a part of the explanation. The aim was to determine whether biomarkers of clot formation (products of von Willebrand Factor formation and activation) and clot resolution (product of fibrin degeneration) during COPD exacerbation predicted major cardiovascular events (MACE). The cohort was based on clinical data and biobank plasma samples from a trial including patients admitted with an acute exacerbation of COPD (CORTICO-COP). Neo-epitope biomarkers of formation and the activation of von Willebrand factor (VWF-N and V-WFA, respectively) and cross-linked fibrin degradation (X-FIB) were assessed using ELISAs in EDTA plasma at the time of acute admission, and analyzed for time-to-first MACE within 36 months, using multivariable Cox proportional hazards models. In total, 299/318 participants had samples available for analysis. The risk of MACE for patients in the upper quartile of each biomarker versus the lower quartile was: X-FIB: HR 0.98 (95% CI 0.65-1.48), VWF-N: HR 1.56 (95% CI 1.07-2.27), and VWF-A: HR 0.78 (95% CI 0.52-1.16). Thus, in COPD patients with an acute exacerbation, VWF-N was associated with future MACE and warrants further studies in a larger population.

KW - COPD exacerbation

KW - major cardiovascular events

KW - coagulation

KW - biomarkers

KW - von Willebrand factor

KW - cross-linked fibrin degradation

KW - VON-WILLEBRAND-FACTOR

KW - D-DIMER

KW - ADAMTS13 ACTIVITY

KW - FACTOR ANTIGEN

KW - MORTALITY

U2 - 10.3390/biomedicines10082011

DO - 10.3390/biomedicines10082011

M3 - Journal article

C2 - 36009558

VL - 10

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 8

M1 - 2011

ER -

ID: 319363416